CClinicalTrials.gg
CompletedNCT04536974SEFIUpdated Jun 12, 2026

The "Self Evaluation of Food Intake" (SEFI) as a Screening Test for Hospital Malnutrition in Children Over 10 Years

An observational study in Malnutrition, Child, sponsored by Rennes University Hospital. Completed at 6 sites in France. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Rennes University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
368
Ages
10 Years to 17 Years
Sex
All
01

Study summary

The goal is to find a simple tool that can be used by medical and paramedical staff and that is reliable to identify children at risk for malnutrition.

Read the detailed description

The Ingesta Easy Assessment Score (SEFI®) (formerly "food intake assessment tool or EPA®") is validated in hospitals in adults to detect the risk of malnutrition and guide nutritional management. SEFI® combines a visual analogue scale (VAS) with a visual assessment of the portions consumed (www.sefi-nutrition.com). It comes in the form of a ruler equipped with a cursor and allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions. consumed (see appendix). A score \<7/10 is associated with malnutrition or the risk of malnutrition.

The investigators hypothesize that, in pediatric services for children 10 years of age or older, SEFI® would be a feasible and reliable tool for screening for the risk of malnutrition.

02

Conditions studied

  • Malnutrition, Child

Keywords

  • MALNUTRITION
  • CHILDREN
  • SEFI
03

In context

Child Nutrition Disorders

164 studies on the registry are indexed under Child Nutrition Disorders; 34 are open to participants now.

This study's enrollment of 368 is above the median of 300 across 31 observational studies indexed under Child Nutrition Disorders.

Browse Child Nutrition Disorders studies →

Lead sponsor

Rennes University Hospital is the lead sponsor of 440 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 10 to 17 and hospitalized in pediatric or pediatric surgery, regardless of the reason for hospitalization

Inclusion criteria

  • Children aged 10 to 17 and hospitalized in pediatric or pediatric surgery, regardless of the reason for hospitalization.
  • Whose holders of parental authority have received information on the protocol and have not expressed their opposition to the child's participation in the study,
  • Having received information on the protocol and not having expressed opposition to participating in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients whose level of understanding does not allow the use of SEFI®
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
368 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testSEFI tool

    Detect the risk of malnutrition with the SEFI tool

06

What researchers measure

Primary outcomes

  1. Assess the reliability of SEFI® for detecting the risk of acute malnutrition in pediatrics

    rate of agreement between the diagnoses of malnutrition obtained by the SEFI® tool and those obtained by diagnostic tools already validated in children: the Weight to Height ratio (or Waterlow index)

    Time frame: 6 month

Secondary outcomes

  1. reliability of SEFI ® to detect the risk of chronic undernutrition in pediatrics

    rate of agreement between the diagnoses of malnutrition obtained by the SEFI® tool and those obtained by diagnostic tools already validated in children: Weight to Age ratio and Height to Age ratio

    Time frame: 6 months

  2. feasibility of SEFI®

    Percentage of completion of the test compared to the number of subjects included in the study (if the test is carried out for each person included = 100% feasibility)

    Time frame: 6 months

  3. correlations of VAS results (score or portions consumed) with occurrence of complications and length of hospital stay

    Duration of hospitalization and complications during hospitalization

    Time frame: 9 months

07

Study locations

6 sites
  • CHU Angers
    Angers, 49000, France
  • CHU Montpellier
    Montpellier, France
  • APHP Trousseau Paris University Hospital
    Paris, 75012, France
  • Rennes University Hospital
    Rennes, 35000, France
  • CHU Toulouse
    Toulouse, 31059, France
  • Tours University Hospital
    Tours, 37044, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536974
Lead sponsor
Rennes University Hospital
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Mar 10, 2021
Primary completion
Nov 8, 2023
Completion
Nov 8, 2023
Last update
Jun 12, 2026

Study contacts

Gauthier Foulon, Doctor
principal investigator · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion